Mostrar el registro sencillo del ítem
dc.contributor.author | Escriche-Navarro, Blanca | es_ES |
dc.contributor.author | Escudero-Noguera, Andrea | es_ES |
dc.contributor.author | Lucena-Sánchez, Elena | es_ES |
dc.contributor.author | Sancenón Galarza, Félix | es_ES |
dc.contributor.author | García-Fernández, Alba | es_ES |
dc.contributor.author | Martínez-Máñez, Ramón | es_ES |
dc.date.accessioned | 2023-03-01T19:02:22Z | |
dc.date.available | 2023-03-01T19:02:22Z | |
dc.date.issued | 2022-09 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/192217 | |
dc.description.abstract | [EN] Cancer immunotherapy has emerged in the past decade as a promising strategy for treating many forms of cancer by stimulating the patient's immune system. Although immunotherapy has achieved some promising results in clinics, more efforts are required to improve the limitations of current treatments related to lack of effective and targeted cancer antigens delivery to immune cells, dose-limiting toxicity, and immune-mediated adverse effects, among others. In recent years, the use of nanomaterials has proven promising to enhance cancer immunotherapy efficacy and reduce side effects. Among nanomaterials, attention has been recently paid to mesoporous silica nanoparticles (MSNs) as a potential multiplatform for enhancing cancer immunotherapy by considering their unique properties, such as high porosity, and good biocompatibility, facile surface modification, and self-adjuvanticity. This review explores the role of MSN and other nano/micro-materials as an emerging tool to enhance cancer immunotherapy, and it comprehensively summarizes the different immunotherapeutic strategies addressed to date by using MSN. | es_ES |
dc.description.sponsorship | B.E.-N., A.E., and E.L.-S. contributed equally to this work. The authors would like to thank the Spanish Government for RTI2018-100910-B-C41 and RTI2018-101599-B-C22 (MCUI/FEDER, EU) and the Generalitat Valenciana (Project PROMETEO 2018/024) for support by Project PROMETEO/2018/024. A.G.-F. acknowledges her current Margarita Salas postdoctoral fellowship from UPV-MIU and "Next Generation EU" program. B.E.-N. is grateful to the Spanish Instituto de Salud Carlos III (ISCIII) for the grant through Project "IFI19/00026", co-funded by European Union. A.E. is grateful for her Ph.D. grant by the Generalitat Valenciana. E.L.-S. thanks MINECO for her FPU fellowship. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Wiley-VCH Verlag GmbH & Co. KGaA | es_ES |
dc.relation.ispartof | Advanced Science | es_ES |
dc.rights | Reconocimiento (by) | es_ES |
dc.subject | Cancer | es_ES |
dc.subject | Checkpoint inhibitors | es_ES |
dc.subject | Immunotherapy | es_ES |
dc.subject | Mesoporous silica nanoparticles | es_ES |
dc.subject | Photodynamic therapies | es_ES |
dc.subject | Vaccines | es_ES |
dc.subject.classification | QUIMICA ORGANICA | es_ES |
dc.subject.classification | QUIMICA INORGANICA | es_ES |
dc.title | Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1002/advs.202200756 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-100910-B-C41/ES/MATERIALES POROSOS INTELIGENTES MULTIFUNCIONALES Y DISPOSITIVOS ELECTRONICOS PARA LA LIBERACION DE FARMACOS, DETECCION DE DROGAS Y BIOMARCADORES Y COMUNICACION A NANOESCALA/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//PROMETEO%2F2018%2F024//Sistemas avanzados de liberación controlada/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-101599-B-C22/ES/DESARROLLO Y APLICACION DE SISTEMAS ANTIMICROBIANOS PARA LA INDUSTRIA ALIMENTARIA BASADOS EN SUPERFICIES FUNCIONALIZADAS Y SISTEMAS DE LIBERACION CONTROLADA/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//IFI19%2F00026/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials | es_ES |
dc.description.bibliographicCitation | Escriche-Navarro, B.; Escudero-Noguera, A.; Lucena-Sánchez, E.; Sancenón Galarza, F.; García-Fernández, A.; Martínez-Máñez, R. (2022). Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. Advanced Science. 9(26):1-24. https://doi.org/10.1002/advs.202200756 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1002/advs.202200756 | es_ES |
dc.description.upvformatpinicio | 1 | es_ES |
dc.description.upvformatpfin | 24 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 9 | es_ES |
dc.description.issue | 26 | es_ES |
dc.identifier.eissn | 2198-3844 | es_ES |
dc.identifier.pmid | 35866466 | es_ES |
dc.identifier.pmcid | PMC9475525 | es_ES |
dc.relation.pasarela | S\476011 | es_ES |
dc.contributor.funder | Generalitat Valenciana | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |
dc.contributor.funder | Universitat Politècnica de València | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad | es_ES |